| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Vaccines Against Tick-Borne Encephalitis Safe, Effective for Young Children: Presented at ESPID By Jenny Powers NICE, France -- May 11, 2010 -- Children as young as 1 year can be protected from tick-borne encephalitis (TBE) with 2 vaccines that are also well tolerated, researchers reported here on May 7 at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Eva Maria Pöllabauer, MD, Global Clinical and Medical Affairs Department, Baxter BioScience, Vienna, Austria, delivered results of an ongoing, single-blind, randomised, clinical study that investigated the immunogenicity and safety of 2 paediatric TBE vaccines (FSME-Immun Junior and Encepur). The vaccine schedule included 2 doses of either FSME-Immun 0.25 mL or Encepur 0.25 mL followed by a third dose of FSME-Immun Junior only in children aged 1 to 11 years. Twenty-eight days following the second vaccination, 100% of children in the FSME-Immun Junior group, were seropositive, compared with 94.0% and 96.7% respectively, in the Encepur group. Local reactions occurred in 12.7% and 8.7% after the 1st and 2nd vaccination with FSME-Immun Junior and in 28.9% and 22.4% with Encepur. The rate of systemic reactions was comparable following the first and second immunisations, respectively with 9.3% and 4.7% occurring in the FSME-Immun Junior group and 11.8% and 5.3% in the Encepur group. Less than 10% of the children in both groups had a mild fever. No serious adverse events were reported. A general trend to higher antibody response was seen in the younger age groups. [Presentation title: Immunogenicity and Safety of Two Tick-Borne Encephalitis Vaccines in Children. Abstract 558]
|